Clinical efficacy of nasal high-frequency ventilation in treatment of neonatal respiratory distress syndrome: a Meta analysis.
- Author:
Yu-Lan YANG
1
;
Ben-Qing WU
;
Jin-Zhen SU
;
Lin YANG
;
Gui-Chao ZHONG
;
Lan LIU
Author Information
1. Department of Neonatology, Second Clinical Medical College of Jinan University, Shenzhen People's Hospital, Shenzhen, Guangdong 518020, China. wubenqing783@126.com.
- Publication Type:Journal Article
- MeSH:
High-Frequency Ventilation;
Humans;
Infant, Newborn;
Infant, Premature;
Intermittent Positive-Pressure Ventilation;
Respiratory Distress Syndrome, Newborn;
Treatment Outcome
- From:
Chinese Journal of Contemporary Pediatrics
2018;20(11):897-903
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To systematically evaluate the clinical efficacy of nasal high-frequency ventilation (nHFV) in the treatment of neonatal respiratory distress syndrome (NRDS).
METHODS:A literature search was performed in PubMed, Cochrane Library, EMBase (Ovid), Chinese Biomedical Literature Database, Chinese Journal Full-text Database, Wanfang Data, and Weipu Data to collect the randomized controlled trials (RCTs) that compared the clinical efficacy of nHFV and nasal continuous positive airway pressure (nCPAP) in the treatment of NRDS. A Meta analysis was performed on the included RCTs using Rev Man 5.3 software after data extraction and quality evaluation by Cochrane 5.1.0.
RESULTS:A total of 4 RCTs involving 218 patients were included. The Meta analysis showed that compared with the nCPAP group, the nHFV group had a significantly better treatment outcome (RR=1.73, 95%CI: 1.39-2.15, P<0.00001). There were no significant differences in the incidence rates of intraventricular hemorrhage, periventricular leukomalacia, bronchopulmonary dysplasia, necrotizing enterocolitis, pneumothorax and retinopathy of prematurity.
CONCLUSIONS:Compared with nCPAP, nHFV has better clinical efficacy in the treatment of NRDS, without increasing the risk of related complications.
